Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin
- 14 February 2011
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 108 (9), 3510-3515
- https://doi.org/10.1073/pnas.1019744108
Abstract
The rapid genetic drift of influenza virus hemagglutinin is an obstacle to vaccine efficacy. Previously, we found that the consensus hemagglutinin DNA vaccine (pCHA5) can only elicit moderate neutralization activities toward the H5N1 clade 2.1 and clade 2.3 viruses. Two approaches were thus taken to improve the protection broadness of CHA5. The first one was to include certain surface amino acids that are characteristic of clade 2.3 viruses to improve the protection profiles. When we immunized mice with CHA5 harboring individual mutations, the antibodies elicited by CHA5 containing P157S elicited higher neutralizing activity against the clade 2.3 viruses. Likewise, the viruses pseudotyped with hemagglutinin containing 157S became more susceptible to neutralization. The second approach was to update the consensus sequence with more recent H5N1 strains, generating a second-generation DNA vaccine pCHA5II. We showed that pCHA5II was able to elicit higher cross-neutralization activities against all H5N1 viruses. Comparison of the neutralization profiles of CHA5 and CHA5II, and the animal challenge studies, revealed that CHA5II induced the broadest protection profile. We concluded that CHA5II combined with electroporation delivery is a promising strategy to induce antibodies with broad cross-reactivities against divergent H5N1 influenza viruses.Keywords
This publication has 37 references indexed in Scilit:
- Hemagglutinin Receptor Binding Avidity Drives Influenza A Virus Antigenic DriftScience, 2009
- Glycans on influenza hemagglutinin affect receptor binding and immune responseProceedings of the National Academy of Sciences, 2009
- Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical DevelopmentsMolecular Therapy, 2009
- A consensus–hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza virusesProceedings of the National Academy of Sciences, 2008
- Recent Avian H5N1 Viruses Exhibit Increased Propensity for Acquiring Human Receptor SpecificityJournal of Molecular Biology, 2008
- Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza VaccinePLOS ONE, 2008
- Three-Dimensional Structure Determines the Pattern of CD4+T-Cell Epitope Dominance in Influenza Virus HemagglutininJournal of Virology, 2008
- Electroporation-based DNA immunisation: translation to the clinicExpert Opinion on Biological Therapy, 2007
- Immunization by Avian H5 Influenza Hemagglutinin Mutants with Altered Receptor Binding SpecificityScience, 2007
- Mapping the Antigenic and Genetic Evolution of Influenza VirusScience, 2004